Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tough week, no doubt
My portfolio is in a depression at the moment...may have to eat dirt ala mode for dinner tonight
There will not be one until after they submit which wu probably be around $1-$1.50 area
RGDL too high too fast...will wait on pullback
Will look at it...watch CDRL go lower now that I text you...I bet I jinxed it lol
Nice. $RDGL about to go up big time!
Morning...there are signs this is stablizing...both my CRDL and WMT calls are green this morning
Im finding more and more playing options
are the way to go if careful
...all depends which way the wind blows
It looks excessive but wouldn’t be surprised to see the $1-1.50 range after it run up with $2 being the area it settles in before its first leg up following this downturn
Im thinking they're diluting because they need money for phase 3 trial...otherwise I dont know why the huge sell off
1.50 could be bottom but 1.75 more likely
$1 bid here if my $1.50’s get filled
I got em...bought 10
Nah...it only allows .05 increments...bidding .15...dont want to bid .20...if doesnt fill will let it go and buy something else...tomorrow is a stock mkt holiday and its summer so a weak mkt is expected
Gm- u get filled?
GM... bidding 6/19 2.50 calls @.15
I’m adding about 500-1k a day for the next couple of weeks
I added a little today...already have plenty...we will do quite well when thos recovers...surprised this crashed
The wrecking ball hit my portflio this morning lol...I'm holding...will wait out this dip
Added this morning and adding more now
Hey we're way oversold here...please add
Yeah they have a low float...so quite volatile
Jump all over this...treat the dip as your friend
CRDL, the old buy-the-rumor, sell-the-news…
Biotechs get big swings, doesn’t mean CRDL won’t work out longer term…
What is happening, why the deep plunge?
$CRDL Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
https://finance.yahoo.com/news/cardiol-therapeutics-announces-positive-topline-115800368.html
Welcome to the Cardiol Therapeutics hotel...our guests sleep well here
Cardiol Therapeutics (NASDAQ:CRDL) is a Canadian biotech drug developer focused on developing their novel ultrapure cannabidiol formulation, CardiolRx™, for rare inflammatory heart diseases, specifically recurrent pericarditis and acute myocarditis.
Pericarditis is characterized as inflammation of the pericardium, layers of tissue that surround the heart, that affects about 165,000 people in the U.S. annually and has no first-line FDA-approved treatment. Among those treated for acute pericarditis, 15% to 30% may experience recurrent pericarditis.
Currently, anti-inflammatory drugs such as colchicine are prescribed for pericarditis treatment in cases of chronic or recurrent pericarditis. If the patient with pericarditis disease does not respond to anti-inflammatory medications, corticosteroids such as prednisone are prescribed.
More recently, Kiniksa Pharmaceuticals’ ARCALYST® (rilonacept) became the first and only FDA-approved treatment indicated for the treatment of recurrent pericarditis and the reduction in risk of recurrence in adults and children 12 years and older.
ARCALYST is a weekly subcutaneous injection, whereas CardiolRx™ is an oral drug taken twice daily which is a major advantage as the idea of weekly injections could not be as appealing to patients.
Cardiol Therapeutics’ (NASDAQ:CRDL) pre-clinical models showed that by inhibiting activation of the NLRP3 inflammasome pathway, cannabidiol may help resolve the symptoms of pericarditis.
This approach has already demonstrated incredible potential, as the company was granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol Therapeutics followed this major achievement with completing enrollment in its Phase 2, open-label MAvERIC-Pilot study investigating the tolerance, safety, and effect of CardiolRx™ in patients with recurrent pericarditis. The primary endpoint of the trial is the change in patient-reported pericarditis pain using an 11-point numeric rating scale (NRS) from baseline to week 8 with topline results expected in early June.
Not only that, Cardiol Therapeutics recently presented its concurrent Phase II ARCHER trial design at the annual congress of the Heart Failure Association of the European Society of Cardiology. This demonstrated the high level of interest from the cardiology community in novel approaches to treat acute myocarditis, for which there are currently no therapies approved by European and US regulatory authorities.
The ARCHER trial is expected to enroll 100 patients at pre-eminent cardiovascular research centers in the United States, Canada, France, Brazil, and Israel. Patient recruitment has been accelerating due in large part to the growing global awareness of myocarditis, and ARCHER has already exceeded 85% of target enrollment.
Cardiol Therapeutics (NASDAQ:CRDL) expects that results from the ARCHER trial will assist in furthering its understanding of the therapeutic potential of CardiolRx™ and will complement the more advanced MAvERIC-Pilot Phase II study in patients with recurrent pericarditis.
Just to put the opportunity here in context, Future Market Insights expects that the worldwide pericarditis treatment market is likely to be worth $ 6 billion by 2032. ARCALYST’s sales further reaffirm this considering that the drug’s 2023 net revenue grew 90% year-over-year to $233.1 million.
Several analysts have maintained their positive outlook on the company and have high hopes that the June data will further prove CardiolRx™ efficacy in treating recurrent pericarditis. In fact, Joe Gantoss of Chimera Research Group notes, “I won’t be surprised to see the price breaking out the 3-year high at $4.96 if the recurrent-pericarditis data show a clear success and open the path to move to the next stage with Phase-3 trial,” while analysts at H.C Wainwright & Co. issued a $9 price target for the stock.
First in first out
Are you picking your nose on this one? You aren't posting...Am I the only one cleaning up here?
Will recover next week
$4 easy then 5
EPIC CALL!!!$$$
CRDL A BEAUTIFUL WEEKLY BREAK OUT!!!
Analysts Think $CRDL is Undervalued
Last week, Canaccord Genuity lifted the PT to $8 from $6 on Cardiol Therapeutics Inc (NASDAQ: CRDL) – Potential gain of 260% from CMP.
Analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and with a PT of $9.
Moreover, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.
$RSLS $MRNA $NVAX $INSM $KTRA $VTYX $SCPX
$CRDL - Analysts Reaffirm Significant Upside Potential for Cardiol Therapeutics
Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) - The company is currently developing CardiolRx™ and CRD-38 therapies for heart diseases, including recurrent pericarditis, acute myocarditis, and heart failure.
The stock has the potential for further upside considering the fact that Cardiol will release topline data for its Phase 2 MAvERIC-Pilot clinical trial evaluating the efficacy of CardiolRx™ for the treatment of recurrent pericarditis sometime in early June, which, if positive, has the potential to send the stock higher.
Several analysts have reiterated that the stock has the potential for significant upside, further reaffirming Cardiol’s growth prospects.
For instance, Joe Gantoss of Chimera Research Group says he won’t be surprised to see Cardiol’s price break past the 3-year high at $4.96 if the recurrent pericarditis data show a clear success and open the path to move to the next stage with Phase 3 trial.
According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in recurrent pericarditis in June that he believes will lead to a positive outcome.
“Clearly, a $160 million market cap does not do Cardiol justice. With positive data in Q2, the path to market becomes a slam dunk, and the stock should surge to the upside in response,” says Gantoss.
In addition, analyst Vernon Bernardino of H.C. Wainwright & Co reiterated their Buy rating and issued a $9 price target, which implies that Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has a potential upside of about 300% from current levels.
Read full details here https://www.nasdaq.com/press-release/analysts-consensus-reaffirms-significant-upside-potential-for-cardiol-therapeutics
Canaccord Genuity - PT Raised By 33% to $8 – Potential 260% rise
$CRDL – More reason to like the stock. Analyst at Canaccord Genuity lifted the PT to $8 from $6 – Potential gain of 260% from CMP
Big Catalyst - Cardiol is conducting an additional open-label Phase II MAvERIC-Pilot study for CardiolRx in recurrent pericarditis. The study is expected to report 8-week top-line data in Early June.
The report Further Says - We have incorporated a $75M equity raise in 3Q24 based on a positive outcome from the recurrent pericarditis Phase II trial. We extended the out-year of our model from a previous 2028 to 2035. We additionally have reduced the EU WAC pricing to 45% of U.S. pricing which is in-line with the current WAC pricing of epidiolex (comparator by mechanism, not indication).
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
191
|
Created
|
10/14/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |